Originally launched in 2014 and updated through 2016, The Antifungal Toolkit: The Pharmacopeia and Beyond is an Internet CME curriculum that provides current information about newer FDA-approved agents/formulations for the management of invasive fungal infections (IFIs) and evaluates their role in strategies to optimize antifungal therapy. In the 2017 updates, we have updated the discussion of newer agents/formulations, emerging agents/diagnostics, and pharmacologic principles/data.
Update 1 Module:
Release Date: 09/30/2017
Expiration Date: 09/29/2018
Estimated Time to Complete the Activity: 0.5 hrs
Media: Interactive, text-based activity
Original Content Module:
Release Date: 03/20/2017
Expiration Date: 03/19/2018
Estimated Time to Complete the Activity: 0.5 hrs
Media: Interactive, text-based activity
Surveys of learners attending or participating in Mycoses Study Group Educational & Research Consortium CME activities identified keeping up to date on emerging therapies and diagnostics as the target audience’s primary antifungal educational need. With postmarketing data for newer FDA-approved agents/formulations, as well as emerging advances in the field, there is a strong educational need to provide clinicians with expert-led insights as well as practical information about these newer agents/formulations in the context of the total antifungal pharmacopeia. These clinicians need to move beyond specific drug knowledge and integrate the information about these newer agents into a well-informed, strategic approach to the overall prophylactic, empiric, preemptive, and definitive treatment of IFIs (ie, competency). Finally, given current requirements of the modern healthcare environment, clinicians also need mastery in antifungal stewardship, which requires knowledge and facility in evaluating the comparative effectiveness as well as pharmacoeconomic data for antifungal agents/strategies in order to inform prudent decision making.
Update 1 Module:
At the conclusion of this activity, the participants will be better able to:
Original Content Module:
This activity is directed to specialists in infectious diseases, hospital medicine, hematology/oncology, pathology, medical microbiology, critical care, pharmacy, and surgery, as well as other healthcare providers responsible for the management of invasive mycoses.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education; Terranova Medica, LLC; and the Mycoses Study Group Educational and Research Consortium.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All speakers, planning committee members and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in these activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
DIMITRIOS P. KONTOYIANNIS, MD, ScD, FACP, FIDSA, PhD Hon, FECMM, FAAP
CONSULTANT:
Amplyx, Inc.; Cidara Therapeutics, Inc.; F2G, Inc.
ADVISORY BOARD:
Merck & Co, Inc.
SPEAKER:
Astellas, Pfizer
RESEARCH SUPPORT:
Astellas, Pfizer
SPEAKERS BUREAU:
Merck & Co, Inc.
RUSSELL E. LEWIS, PHARMD, FCCP, BCPS
RESEARCH SUPPORT:
Merck
ADVISORY BOARD:
Merck
SPEAKERS BUREAU/FACULTY/PEER REVIEWER:
Gilead Inc.; Merck; and Basilea
DAVID R. ANDES, MD
RESEARCH SUPPORT:
Astellas Pharma US; Merck; Scynexis; Amplyx; Zavante; Cidara; Theravance; The Medicines Company; Paratek
ADVISORY BOARD/CONSULTANT:
Astellas Pharma US; Merck & Co; Cubist
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs
LOIS COLBURN
UNMC Center for Continuing Education
No conflicts to disclose.
BRENDA C. RAM, CMP, CHCP
UNMC Center for Continuing Education
No conflicts to disclose.
ALISON FREIFELD, MD
University of Nebraska Medical Center
DATA SAFETY MONITORING BOARD:
Astellas; Merck & Co., Inc.
LISA A. TUSHLA, PHD, H(ASCP)
Terranova Medica, LLC
No conflicts to disclose
To receive a CME certificate of participation, participants should:
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and UNMC CCE are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
To earn CME credits using the website, the UNMC CCE requires submission of certain personally identifiable information. The required items include: first name, last name, degree, and e-mail address. These items are necessary to award and track the credits that participants may earn after completing the program. To obtain credit, learners must complete an evaluation of the CME activity. This information is used in a continuous improvement process to enhance the learning experience of future programs.
Terranova Medica, LLC, and UNMC CCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing Education; the Mycoses Study Group Education & Research Consortium; and Terranova Medica, LLC.
Healthcare professionals and other individuals should review and consider other publications and materials on the subject before relying solely upon the information contained within this educational activity.
There is no charge for this activity.
This activity is supported by an independent educational grant from Astellas.
For further information, contact Tom Davis by telephone (877-276-4523), fax (805-648-8070), or email (tdavis@terranovamedica.com).
Copyright ©2017 UNMC CCE; Terranova Medica, LLC; and MSG-ERC.
